If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
=== Pharmacokinetics === The half-life of endogenous insulin once it enters the bloodstream is 4 to 6 minutes. This allows the endocrine system to rapidly adapt to changing conditions within the body. Exogenous insulin, however, would not be effective with a short half-life, as it would require continuous injection or infusion to have the desired effect. While it is difficult to change the rate at which the protein is metabolized in the bloodstream, it is possible to alter how fast the protein is absorbed from the site of injection in various ways. Lente insulin was formulated by the addition of zinc to the crude porcine and bovine insulin extracts, which causes the insulin protein to form larger crystals which dissolve into the body slower upon injection. This means that while the insulin in the bloodstream is still metabolized in 4–6 minutes, more insulin is continually being absorbed from the dose injected for hours after administration. Compared to NPH insulin, another intermediate acting insulin, up to 40% of the dose of lente insulin may remain unabsorbed for over 24 hours after administration. The variation in absorption between doses in the same patient of lente insulin is comparable to that of insulin NPH. The distribution of insulin is not well understood, but it is known that it is heavily bound to receptors throughout the body (approximately 80% to receptors on liver cells) and metabolized in large part by phase one processes in the liver.
=== Protein localization === Finding the location of proteins allows us to predict what they do. This is called protein function prediction. For instance, if a protein is found in the nucleus it may be involved in gene regulation or splicing. By contrast, if a protein is found in mitochondria, it may be involved in respiration or other metabolic processes. There are well developed protein subcellular localization prediction resources available, including protein subcellular location databases, and prediction tools.
Plant resin is a viscoelastic solid polymer. When left in a container, it will flow slowly as a liquid to conform to the contours of its container. If struck with greater force, however, it will shatter as a solid.
Richmond – This rivalry stems out of the 1942 Grand Final which Essendon won. In 1974, a half-time brawl took place involving trainers, officials and players at Windy Hill and has become infamous as one of the biggest ever. The teams didn't meet in the finals between 1944 and 1995, but there have been many close margins in home and away season matches as a result of each team's "never say die" attitude and ability to come back from significant margins in the dying stages of matches. Having met in the AFL's Rivalry Round in (2006 and 2009) and meeting in the Dreamtime at the 'G match since 2005, the rivalry and passion between the clubs and supporters has re-ignited. In recent years the rivalry has been promoted as the "Clash of the Sash". Hawthorn – The two sides had a number of physical encounters in the mid-1980s when they were the top two sides of the competition. The rivalry was exacerbated when Dermott Brereton ran through Essendon's three-quarter time huddle during a match in 1988 and again by an all in brawl during a match in 2004 allegedly instigated by Brereton (now known as the Line in the Sand Match after the direction allegedly given by Brereton for the Hawthorn players to make a physical stand). This was reminiscent of the 1980s when battles with Hawthorn were often hard and uncompromising affairs. During Round 22 of the 2009 season, Essendon and Hawthorn played for the last finals spot up for grabs. The teams played out an extremely physical game and despite being 22 points down at half time Essendon went on to win by 17 points.
Sources: en.wikipedia.org
=== Cost === GLP-1 agonists are more expensive than other treatments for type 2 diabetes. A study compared the cost-effectiveness of GLP-1 agonists to long-acting insulin in a Taiwanese population with type 2 diabetes. In people with cardiovascular disease (CVD), GLP-1 agonists were estimated to save money due to fewer cardiovascular incidents. In people without CVD, the cost per QALY was $9,093. In the United States, cost is the highest barrier to GLP-1 agonist usage and was reported as the reason for discontinuation in 48.6% of people who stopped using the drugs. According to a 2023 study, GLP-1 agonists were not cost-effective for pediatric obesity in the U.S. As of late 2025, prices had dropped substantially. In 2025 it was estimated that Medicare coverage of GLP-1RA agonists for obesity in the United States would increase federal spending by $69.5 billion over a decade. Mixed results have been found when economic evaluations of glucagon like peptide-1 (GLP-1) receptor agonists have been done, specifically in response to its use for obesity treatment in people without diabetes. A 2026 review concluded that, due to their high acquisition costs, GLP-1 receptor agonists are generally not cost-effective compared to lifestyle interventions or no treatment at all from a healthcare-payer perspective. The analysis also reported that cost-effectiveness outcomes vary drastically depending on assumptions related to treatment duration, long-term weight maintenance, and the time horizon of the specific model.
== Future Applications == Reticular cells were once considered passive structural elements. However, they are now being recognized as potential regulators of immune function. Their influence extends from organizing lymphoid tissue to now even directing immune responses and contributing to tumor regulation. As researchers continue to uncover the complexity of these cells, new technologies such as single-cell RNA sequencing are being used to provide more insight into their genetic diversity and viability in the body. Future studies will likely focus on manipulating these cells to improve immune therapies, including against tumors which could be extremely beneficial in the world of medicine.. By mapping how each subtype interacts with immune cells and signaling molecules in the body, scientists may be able to utilize reticular cells to enhance vaccine responses and accelerate wound healing. Lütge, Pikor, and Ludewig (2021) emphasize that understanding the cellular differences of different reticular cell subtypes will be critical for developing targeted treatments that alter the immune system safely and effectively. In conclusion, reticular cells occupy many unique positions in tissue structure and offer the human body immune regulation. Continued exploration of their biological structure and interactions will not only deepen our understanding of the immune system but may also alter how clinicians approach diseases that involve immune system irregularities.
== Pathophysiology == As of 2016, the pathophysiology of tendinopathy was poorly understood. While inflammation plays a role, the relationships among changes to the structure of tissue, the function of tendons, and pain are not understood. Several models are proposed, none of which have been fully validated or falsified. Molecular mechanisms involved in inflammation include release of inflammatory cytokines such as IL-1β which reduce the expression of type I collagen mRNA in human tenocytes and cause extracellular matrix degradation in the tendon. A 2020 review noted that while various inflammatory markers were present in two thirds of the reviewed articles, data heterogeneity and lack of comparable studies prevented any conclusion about a common pathophysiology. Multifactorial theories include tensile overload, tenocyte-related collagen synthesis disruption, load-induced ischemia, neural sprouting, thermal damage, and adaptive compressive responses. The intratendinous sliding motion of fascicles and shear force at interfaces of fascicles could predispose tendons to rupture. The most commonly accepted cause is an overuse syndrome in combination with factors leading to what may be seen as a progressive interference or the failing of the innate healing response. Tendinopathy involves apoptosis, matrix disorganization and neovascularization. Classic characteristics include degenerative changes in the collagenous matrix, hypercellularity, hypervascularity, and a lack of inflammatory cells, which has challenged the misnomer "tendinitis".
Indeed, during the early penicillin era, the drug was so scarce and so highly valued that it became common to collect the urine from patients being treated, so that the penicillin in the urine could be isolated and reused. This was not a satisfactory solution, so researchers looked for a way to slow penicillin excretion. They hoped to find a molecule that could compete with penicillin for the organic acid transporter responsible for excretion, such that the transporter would preferentially excrete the competing molecule and the penicillin would be retained. The uricosuric agent probenecid proved to be suitable. When probenecid and penicillin are administered together, probenecid competitively inhibits the excretion of penicillin, increasing penicillin's concentration and prolonging its activity. Eventually, the advent of mass-production techniques and semi-synthetic penicillins resolved the supply issues, so this use of probenecid declined. Probenecid is still useful, however, for certain infections requiring particularly high concentrations of penicillins. After the Second World War Australia was the first country to make the drug available for civilian use. In the United States penicillin was made available to the general public on 15 March 1945. Fleming, Florey and Chain shared the 1945 Nobel Prize in Physiology or Medicine for the development of penicillin.
Side effects from therapeutic use can be much more varied depending on the location of injection and the dose of toxin injected. In general, side effects from therapeutic use can be more serious than those that arise during cosmetic use. These can arise from paralysis of critical muscle groups and can include arrhythmia, heart attack, and in some cases, seizures, respiratory arrest, and death. Additionally, side effects common in cosmetic use are also common in therapeutic use, including trouble swallowing, muscle weakness, allergic reactions, and flu-like syndromes. In response to the occurrence of these side effects, in 2008, the US Food and Drug Administration (FDA) notified the public of the potential dangers of the botulinum toxin as a therapeutic. Namely, the toxin can spread to areas distant from the site of injection and paralyze unintended muscle groups, especially when used for treating muscle spasticity in children treated for cerebral palsy. In 2009, the FDA announced that boxed warnings would be added to available botulinum toxin products, warning of their ability to spread from the injection site. However, the clinical use of botulinum toxin A in children with cerebral palsy has been proven to be safe with minimal side effects. Additionally, the FDA announced name changes to several botulinum toxin products, to emphasize that the products are not interchangeable and require different doses for proper use.
Sources: en.wikipedia.org
The actual chain elongation occurs through condensation between malonyl-mtACP and the growing acyl-mtACP (with acetyl-mtACP in the first round) by 3-oxoacyl-ACP synthase (OXSM), releasing CO2 and extending the chain by two carbons. Next, the newly extended fatty acyl chain on mtACP (3-ketoacyl-mtACP) undergoes reduction by the mitochondrial 3-ketoacyl-ACP reductase (mtKAR; composed of HSD17B8 and CBR4), dehydration by 3-hydroxyacyl-ACP dehydratase 2 (HTD2), and a final reduction by trans-2-enoyl-CoA reductase (MECR). The last three steps restore the fatty acyl chain to its saturated state prior to condensation, making it available for the next elongation cycle. NADPH, the electron donor required for the reduction steps, fuels the mtFAS pathway and is derived from NADP+ produced by NADK2. These steps repeat until the required chain length is reached, generating mtACP-bound fatty acyl chains ranging from C2 to C16. Since no mitochondrial acyl-mtACP thioesterase has been identified in any animal species, the final products of mtFAS remain bound to mtACP rather than being released as free fatty acids.
The East Prussian plebiscite (German: Volksabstimmung in Ostpreußen), also known as the Allenstein and Marienwerder plebiscite or Warmia, Masuria and Powiśle plebiscite (Polish: Plebiscyt na Warmii, Mazurach i Powiślu), was a plebiscite for the self-determination of the regions of southern Warmia (Ermland), Masuria (Mazury, Masuren) and Powiśle, which had been in parts of the East Prussian Government Region of Allenstein and of the West Prussian Government Region of Marienwerder in accordance with Articles 94 to 97 of the Treaty of Versailles. Prepared in early 1920, the plebiscite took place on 11 July 1920 and was conducted by German authorities under Inter-Allied control. The plebiscite reported that most voters had selected East Prussia over Poland (over 97% in the Allenstein Plebiscite Area and 92% in the Marienwerder Plebiscite Area). As a result, most of the territories in question remained in the Free State of Prussia and therefore in Germany.
ribosome A macromolecular complex made of both RNA and protein which serves as the site of protein synthesis by translation. Ribosomes have two subunits, each of which consists of one or more strands of ribosomal RNA bound to various ribosomal proteins: the small subunit, which reads the messages encoded in messenger RNA molecules, and the large subunit, which links amino acids in sequence to form a polypeptide chain. Ribosomes are essential and ubiquitous in all cell types and are used by all known forms of life.
Semiconducting CNTs are more strongly attracted by gel than metallic CNTs. While it shows potential, this application is limited to the separation of semiconducting (n,m) species. ATPE uses two water-soluble polymers such as polyethylene glycol (PEG) and dextran. When mixed, two immiscible aqueous phases form spontaneously, and each of the two phases shows a different affinity to CNTs. Partition depends on the solvation energy difference between two similar phases of microscale volumes. By changing the separation system or temperatures, and adding strong oxidants, reductants, or salts, the partition of CNTs species into the two phases can be adjusted. Despite the progress that has been made to separate and purify CNTs, many challenges remain, such as the growth of chirality-controlled CNTs, so that no further purification is needed, or large-scale purification.
=== Termination complex === Once eRF1 recognizes the stop codon and binds to the ribosome, eRF1 is ready for the final steps of termination: hydrolysis of the peptide bond. In order to release the polypeptide from the p site of the ribosome, an additional protein, energy source, and ions are needed to aid eRF1, which is achieved by forming a quaternary complex. The additional protein is eRF3, which is a GTPase, the energy source is a GTP molecule, and the ion is a Mg2+. Once eRF3 is bound to eRF1, its affinity for GTP increases significantly compared to the affinity of a solo eRF3 protein. It is worth noting that stop codon recognition does not require GTP, whereas hydrolysis of peptidyl tRNA and release of the termination complex does require GTP.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.